Regulus Therapeutics Inc. (RGLS)

Name: Regulus Therapeutics Inc. (RGLS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Regulus Therapeutics Inc. (RGLS)

Stock Card

$8.16

$0.00 (0.00%)

As on 25-Jun-2025 09:30EDT

Market cap

$565 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

8.2

Div. Yield

0 %

Regulus Therapeutics (RGLS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 8.16 High: 8.16

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.6
Debt to Equity

0
Book Value

$--
EPS

$-0.7
Face value

--
Shares outstanding

69,234,096

10 Years Aggregate

CFO

$-357.08 Mln

EBITDA

$-396.66 Mln

Net Profit

$-434.90 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Regulus Therapeutics (RGLS)	416.5	3.4	466.7	298.0	50.2	0.0	-39.4
BSE Sensex^*	-8.8	0.5	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 25-Jun-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2021	2020	2019	2018
Regulus Therapeutics (RGLS)	23.2	-6.6	-76.3	51.7	-4.4	-92.4
S&P Small-Cap 600	7.0	13.9	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting... miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG. Read more

CEO & Director

Mr. Joseph P. Hagan M.B.A.
CEO & Director

Mr. Joseph P. Hagan M.B.A.
Headquarters

San Diego, CA
Website

https://www.regulusrx.com

FAQs for Regulus Therapeutics (RGLS)

What is the current share price of Regulus Therapeutics Inc (RGLS) Today?

The share price of Regulus Therapeutics Inc (RGLS) is $8.16 (NASDAQ) as of 25-Jun-2025 09:30 EDT. Regulus Therapeutics Inc (RGLS) has given a return of 50.24% in the last 3 years.

What is the current PB & PE ratio of Regulus Therapeutics Inc (RGLS)?

Since, TTM earnings of Regulus Therapeutics Inc (RGLS) is negative, P/E ratio is not available.
The P/B ratio of Regulus Therapeutics Inc (RGLS) is 8.19 times as on 25-Jun-2025, a 53 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-2.23	1.35
2023	-0.86	1.22
2022	-0.81	0.69
2021	-0.12	0.06
2020	-0.42	0.25

What is the 52 Week High and Low of Regulus Therapeutics Inc (RGLS)?

The 52-week high and low of Regulus Therapeutics Inc (RGLS) are Rs -- and Rs -- as of 28-Aug-2026.

What is the market cap of Regulus Therapeutics Inc (RGLS)?

Regulus Therapeutics Inc (RGLS) has a market capitalisation of $ 565 Mln as on 25-Jun-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Regulus Therapeutics Inc (RGLS)?

Before investing in Regulus Therapeutics Inc (RGLS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.